Cargando…

Clear cell adenocarcinoma of female urethra: A case report

Primary malignancies of the female urethra are rare, accounting for less than 1% of genitourinary malignancies. Clear cell adenocarcinoma of the urethra (CCAU) occurs more infrequently, accounting for 0.003% of malignancies of the female urogenital tract. Definitive clinical diagnosis of CCAU is dif...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartman, Kasondra, Li, Jinghong, Garg, Tullika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991334/
https://www.ncbi.nlm.nih.gov/pubmed/29888186
http://dx.doi.org/10.1016/j.eucr.2018.04.008
_version_ 1783329793911029760
author Hartman, Kasondra
Li, Jinghong
Garg, Tullika
author_facet Hartman, Kasondra
Li, Jinghong
Garg, Tullika
author_sort Hartman, Kasondra
collection PubMed
description Primary malignancies of the female urethra are rare, accounting for less than 1% of genitourinary malignancies. Clear cell adenocarcinoma of the urethra (CCAU) occurs more infrequently, accounting for 0.003% of malignancies of the female urogenital tract. Definitive clinical diagnosis of CCAU is difficult and must be differentiated from tumors of the vagina. Currently, there is limited understanding of the causes of CCAU and there is no established standard of care for treatment. Immunohistochemistry and pathologic analysis can be used to identify the origin of the tumor.
format Online
Article
Text
id pubmed-5991334
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-59913342018-06-08 Clear cell adenocarcinoma of female urethra: A case report Hartman, Kasondra Li, Jinghong Garg, Tullika Urol Case Rep Oncology Primary malignancies of the female urethra are rare, accounting for less than 1% of genitourinary malignancies. Clear cell adenocarcinoma of the urethra (CCAU) occurs more infrequently, accounting for 0.003% of malignancies of the female urogenital tract. Definitive clinical diagnosis of CCAU is difficult and must be differentiated from tumors of the vagina. Currently, there is limited understanding of the causes of CCAU and there is no established standard of care for treatment. Immunohistochemistry and pathologic analysis can be used to identify the origin of the tumor. Elsevier 2018-05-07 /pmc/articles/PMC5991334/ /pubmed/29888186 http://dx.doi.org/10.1016/j.eucr.2018.04.008 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Hartman, Kasondra
Li, Jinghong
Garg, Tullika
Clear cell adenocarcinoma of female urethra: A case report
title Clear cell adenocarcinoma of female urethra: A case report
title_full Clear cell adenocarcinoma of female urethra: A case report
title_fullStr Clear cell adenocarcinoma of female urethra: A case report
title_full_unstemmed Clear cell adenocarcinoma of female urethra: A case report
title_short Clear cell adenocarcinoma of female urethra: A case report
title_sort clear cell adenocarcinoma of female urethra: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991334/
https://www.ncbi.nlm.nih.gov/pubmed/29888186
http://dx.doi.org/10.1016/j.eucr.2018.04.008
work_keys_str_mv AT hartmankasondra clearcelladenocarcinomaoffemaleurethraacasereport
AT lijinghong clearcelladenocarcinomaoffemaleurethraacasereport
AT gargtullika clearcelladenocarcinomaoffemaleurethraacasereport